ampelopsin has been researched along with Bone Loss, Osteoclastic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Cai, Q; Fan, KJ; Wang, QS; Wang, TY; Wu, J; Xu, BX | 1 |
Chen, A; Fang, H; Fang, J; Guo, F; Hou, X; Huang, S; Li, F; Li, X; Zhang, X | 1 |
2 other study(ies) available for ampelopsin and Bone Loss, Osteoclastic
Article | Year |
---|---|
DMY protects the knee joints of rats with collagen-induced arthritis by inhibition of NF-κB signaling and osteoclastic bone resorption.
Topics: Animals; Arthritis, Experimental; Bone Resorption; Cartilage, Articular; Cell Line; Collagen; Flavonols; Knee Joint; Male; NF-kappa B; Osteoblasts; Osteoclasts; RANK Ligand; Rats; Rats, Wistar; Signal Transduction | 2020 |
(2R,3R)Dihydromyricetin inhibits osteoclastogenesis and bone loss through scavenging LPS-induced oxidative stress and NF-κB and MAPKs pathways activating.
Topics: Animals; Bone Resorption; Flavonols; Lipopolysaccharides; Male; Mice; Mitogen-Activated Protein Kinases; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Osteogenesis; Oxidative Stress; RAW 264.7 Cells; Reactive Oxygen Species; Signal Transduction; Superoxide Dismutase | 2018 |